FireFly Neuroscience Announces Healthcare Science and AI Industry Leader David DeCaprio to Join Board of Directors

Board Appointment is a Key Step Towards Anticipated Trading on NASDAQ

FAIRFAX, Va. and TORONTO, April 17, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”), a pioneering AI company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, announces that Healthcare Science and AI Industry leader, David DeCaprio (“DeCaprio”), has entered into an agreement to join the Company’s Board of Directors upon completion of the anticipated merger with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD). This appointment is a key step towards Firefly’s anticipated start of trading on the NASDAQ.

DeCaprio has significant experience transitioning advanced technology from academic research labs into successful businesses. He is a Co-founder of ClosedLoop.ai, which has been recognized as the #1 AI platform for healthcare from 2022 through 2024. Additionally, he was the winner of the CMS AI Health Outcomes Challenge and was an Engineering Lead for the Human Genome Project at the Broad Institute of MIT and Harvard.

“With the upcoming merger with WaveDancer and subsequent listing on NASDAQ, we are entering a transformational moment in the history of the Company,” said Jon Olsen, CEO of Firefly. “We are honored to welcome Mr. DeCaprio to Firefly’s Board of Directors, and we look forward to leveraging Mr. DeCaprio’s breadth and depth of expertise as we continue to develop innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders.”

About Firefly

Firefly is a medical technology and AI company developing and pioneering innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics (“BNA”) software platform (the “Platform”) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). Over the last 15 years the Company has invested approximately $60 million to develop its BNA software, compile a database of brain wave tests, gain patent protection, and receive FDA approval to market and sell the Platform. As a result, Firefly is now pursuing commercial launch of the BNA Platform in multiple markets including, pharmaceutical companies with drug research and clinical trial activities and medical practitioners for use in their clinics.